Intuitive Surgical (ISRG): Q3 2026 Earnings Review
Read next
Are RSV vaccines going to be the next blockbuster vaccine to be developed?
The below graph shows that the rate of RSV-associated hospitalizations has increased significantly after the COVID pandemic (2020-2021 season).
In the 2022-2023 season, the current estimate for RSV-associated hospitalization stood at 18 per 100k people in the US. However, this is just the start of the
3 Top Biotech News Of The Week (22 Oct 2022) - Oculis, LLY, AKUS, JAZZ, ZYME
1) Another ophthalmology acquisition: Oculis. SA and European Biotech Acquisition Corp. announce business combination agreement
The resultant company, Oculis Holding SA will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline therapeutics for diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma.
Oculis’ pipeline
A look at Nimbus & Eli Lilly's AMPK Collaboration, Regeneron and Sanofi's Dupixent EOE approval and Merck's Sotatercept for PAH
1) Eli Lilly (NYSE: LLY) enters into collaboration with Nimbus to develop therapeutics for metabolic diseases
Eli Lilly and Nimbus enter into a collaboration to develop therapeutics for metabolic diseases.
The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK